Vivoryon Therapeutics N.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vivoryon Therapeutics N.V.
Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.
New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.
Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.
Probiodrug is ramping up plans to run Phase IIb Alzheimer's disease trials on the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy. CEO Konrad Glund spoke to Scrip at the 2018 Biotech Showcase.
- Other Names / Subsidiaries
- Probiodrug AG
- Vivoryon Therapeutics AG